Albert Rizzo, MD, on the Annual State of Lung Cancer Report


The American Lung Association’s annual “State of Lung Cancer” (SOLC) report tracked the toll of lung cancer at national and state levels, identifying both promising improvements for the overall population and significant health disparities for racial and ethnic minorities.

For the first time, the American Lung Association’s annual “State of Lung Cancer” (SOLC) report examined the burden of lung cancer among racial and ethnic groups at the national and state levels.

The report found that people of color who are diagnosed with lung cancer are less likely to be diagnosed early, less likely to receive surgical treatment, and more likely to receive no treatment. Moreover, the reported indicated that lack of access to quality and affordable health care is a key contributor of these worse outcomes.

“The ‘State of Lung Cancer’ highlights that too many people are being left behind when it comes to making progress against lung cancer,” Harold Wimmer, president and CEO of the American Lung Association, said in a press release. “We must all do more to address lung cancer, for all communities.”

In an interview with CancerNetwork®, Albert Rizzo, MD, chief medical officer of the American Lung Association, discussed the findings of this year’s report and what he believes still needs to be accomplished for patients with lung cancer.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.


‘State of Lung Cancer’ Report Finds People of Color Face Greater Burden, Worse Lung Cancer Outcomes [news release]. Chicago. Published November 17, 2020. Accessed December 11, 2020.

Related Videos
Expert on NSCLC
Experts on NSCLC
Expert on NSCLC
Expert on NSCLC
Experts on NSCLC
Expert on NSCLC
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
Related Content